🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

RecruitingPhase 3Ages 18 Years - 60 YearsAllKhyber Medical University Peshawar
NCT07703722 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Trauma-related Major Depressive Disorder (MDD) is frequently associated with poor response to conventional antidepressants, persistent psychological distress, and alterations in gut-brain axis function. Existing assessment tools primarily diagnose depression or PTSD but provide limited guidance for integrated clinical management. This study aims to develop and validate the Trauma Anxiety Depression Emotion (TADE) management tool while simultaneously evaluating the effectiveness of psilocybin-assisted Structured Integrated Reframing Therapy (SIRT) in improving clinical and biological outcomes. This prospective, four-arm randomized controlled trial will compare conventional therapy, psilocybin therapy, SIRT, and psilocybin-assisted SIRT. Participants will undergo assessment using the newly developed TADE tool together with established psychometric scales including HAM-D, PCL-5, and GAD-7.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18-60 years. * Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria. * Trauma-related depression with clinically significant trauma symptoms. * Hamilton Depression Rating Scale (HAM-D) score \>16. * PTSD Checklist for DSM-5 (PCL-5) score \>33. * Generalized Anxiety Disorder-7 (GAD-7) score \>10. * Receiving a stable single SSRI antidepressant regimen for at least 6 weeks before enrollment with adequate treatment adherence. * Able and willing to provide written informed consent. * Willing to comply with all study procedures and follow-up visits. * Women of childbearing potential must agree to use effective contraception throughout the study. Exclusion Criteria: * Significant cardiovascular disease. * Clinically significant hepatic or renal impairment. * Significant neurological disorders. * Current or past psychotic disorder or bipolar disorder. * Current substance or alcohol use disorder, including ketamine or psychedelic drug use. * Use of more than one antidepressant medication. * Pregnancy, planned pregnancy, or breastfeeding. * Known hypersensitivity or contraindication to psilocybin. * Participation in another interventional clinical trial within the previous 30 days. * Inability or unwillingness to provide informed consent. * Any medical or psychiatric condition that, in the investigator's opinion, would interfere with safe participation or study assessments.
💊

What it tests

  • Psilocybin
  • Structured Integrated Reframing Therapy (SIRT)
  • Selective Serotonin Reuptake Inhibitor (SSRI)
📍

Where

3 sites
Institute of Health Science, Khyber Medical University
Islamabad, Pakistan
Hayatabad Medical Complex Peshawar
Peshawar, Pakistan
Khyber Medical University
Peshawar, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy